NFKB1 and cancer: Furthermore, TA is a negative regulator of signaling pathways associated with cancer-cell metastasis and therapy resistance, including the TGF-β, Notch, Wnt, AKT-mTOR, MAPK/ERK, and NF-κB pathways [32,33].